Bullfrog AI Holdings, Inc. Common Stock (BFRG) Stock

Bullfrog AI Holdings, Inc. Common Stock (BFRG) is a Healthcare stock trading at $0.67 (as of 2026-05-22), with a market capitalization of $10.81M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cannot produce an SEC-based company description because the text of the company’s SEC 10-K Item 1 “Business” was not provided. Please share that section so the description can be written using only the primary source.

Understand Bullfrog AI Holdings, Inc. Common Stock: how it makes money

Bullfrog AI Holdings is a digital biopharmaceutical company that uses AI/ML to analyze preclinical and clinical medicine data in the United States, and it makes money through its bfLEAP AI/ML platform and licensing agreements (including rights related to siRNA targeting Beta2-spectrin via George Washington University).

The core profit model likely depends on monetizing two value streams described by the company, adoption of its bfLEAP AI/ML platform for analyzing medical and healthcare data, and licensing and commercialization of its George Washington University siRNA targeting rights for specific diseases.

Business quality (Weak): The business description is clear, but the provided data includes no reportable segments and no operational KPIs, so it is harder to assess what specific operating metrics drive performance. The latest provided quarter also shows revenue as 0.0B and a very large negative operating margin.

Bull case

  • AI/ML platform for biopharma analysis: The company offers bfLEAP, an AI/ML platform for analyzing preclinical and/or clinical data in medicine and healthcare.
  • IP and licensing-based programs: It has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in treating human diseases including hepatocellular carcinoma, obesity, and non-alcoholic fatty liver disease.

Bear case

  • Loss-making economics in the latest provided quarter: For the period ending 2026-03-31, operating margin is reported as -9851.9 (very negative).
  • Revenue is shown as zero in the latest provided quarter: In the same latest provided period (2026-03-31), revenue is shown as 0.0B, which limits visibility into monetization.
Valuation — source: SEC EDGAR (first-party)
Price$0.67
Market Cap$10.81M
EV / EBITDA-0.6
Price / Book1.55
Price / Sales36.18
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$116670.00
Net Margin-5569.6%
Return on Equity-85.8%
Debt / Equity0.01
Current Ratio10.57
Financial Health — source: SEC EDGAR
Altman Z-Score-10.96 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJ. Safra Sarasin Holding AG ($191050.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOVininder Singh
Employees4
CountryUS
IPO Date2023-02-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • BioVie Inc. (BIVI)
  • Phio Pharmaceuticals Corp. (PHIO)
  • Moleculin Biotech, Inc. (MBRX)
  • Kiora Pharmaceuticals, Inc. (KPRX)
  • Aspire Biopharma Holdings, Inc. (ASBP)
  • Theriva Biologics, Inc. (TOVX)
  • MetaVia Inc. (MTVA)
  • Imunon, Inc. (IMNN)
BFRG earnings history · BFRG institutional & insider holders · BFRG KPIs & operating metrics · BFRG financials · BFRG investor presentations & press releases · BFRG SEC filings · BFRG peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-05-22.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.